Selected research
Market Analysis & Forecast
Global Retinal Disorders Therapy Market Analysis and Forecast 2026-2032
Market perspective
The global Retinal Disorders Therapy market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Retinal Disorders Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Retinal Disorders Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Retinal Disorders Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Retinal Disorders Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Retinal Disorders Therapy include ALLERGAN, Alimera Sciences, Bausch & Lomb, Bristol-Myers Squibb, Genentech, Genzyme, Janssen Biotech, OCULAR THERAPEUTIX and Swedish Orphan Biovitrum, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Retinal Disorders Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Retinal Disorders Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for Retinal Disorders Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Retinal Disorders Therapy revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Retinal Disorders Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Retinal Disorders Therapy revenue, projected growth trends, production technology, application and end-user industry.
Retinal Disorders Therapy Segment by Company
ALLERGAN
Alimera Sciences
Bausch & Lomb
Bristol-Myers Squibb
Genentech
Genzyme
Janssen Biotech
OCULAR THERAPEUTIX
Swedish Orphan Biovitrum
UCBCares
AbbVie
Eyebright Medical
Aier Eye Hospital
Alcon Holdings, Inc.
Huaxia Eye Hospital
Kanghong Pharmaceutical
Roche
Xingqi Pharmaceutical
Retinal Disorders Therapy Segment by Type
Ocular Inflammatory Disease (Uveitis)
Diabetic Retinopathy
Age Related Macular Degeneration
Macular Hole
Retinal Disorders Therapy Segment by Application
Hospitals
Clinics
Others
Retinal Disorders Therapy Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Retinal Disorders Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Retinal Disorders Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Retinal Disorders Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Retinal Disorders Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Retinal Disorders Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Retinal Disorders Therapy revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Ocular Inflammatory Disease (Uveitis)
- Diabetic Retinopathy
- Age Related Macular Degeneration
- Macular Hole
Applications
- Hospitals
- Clinics
- Others
Companies covered
- ALLERGAN
- Alimera Sciences
- Bausch & Lomb
- Bristol-Myers Squibb
- Genentech
- Genzyme
- Janssen Biotech
- OCULAR THERAPEUTIX
- Swedish Orphan Biovitrum
- UCBCares
- AbbVie
- Eyebright Medical
- Aier Eye Hospital
- Alcon Holdings, Inc.
- Huaxia Eye Hospital
- Kanghong Pharmaceutical
- Roche
- Xingqi Pharmaceutical
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Retinal Disorders Therapy Market by Type
- 1.2.1 Global Retinal Disorders Therapy Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Ocular Inflammatory Disease (Uveitis)
- 1.2.3 Diabetic Retinopathy
- 1.2.4 Age Related Macular Degeneration
- 1.2.5 Macular Hole
- 1.3 Retinal Disorders Therapy Market by Application
- 1.3.1 Global Retinal Disorders Therapy Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Hospitals
- 1.3.3 Clinics
- 1.3.4 Others
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Retinal Disorders Therapy Market Dynamics
- 2.1 Retinal Disorders Therapy Industry Trends
- 2.2 Retinal Disorders Therapy Industry Drivers
- 2.3 Retinal Disorders Therapy Industry Opportunities and Challenges
- 2.4 Retinal Disorders Therapy Industry Restraints
3 Global Growth Perspective
- 3.1 Global Retinal Disorders Therapy Market Perspective (2021-2032)
- 3.2 Global Retinal Disorders Therapy Growth Trends by Region
- 3.2.1 Global Retinal Disorders Therapy Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Retinal Disorders Therapy Market Size by Region (2021-2026)
- 3.2.3 Global Retinal Disorders Therapy Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Retinal Disorders Therapy Revenue by Players
- 4.1.1 Global Retinal Disorders Therapy Revenue by Players (2021-2026)
- 4.1.2 Global Retinal Disorders Therapy Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Retinal Disorders Therapy Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Retinal Disorders Therapy Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Retinal Disorders Therapy Key Players Headquarters & Area Served
- 4.4 Global Retinal Disorders Therapy Players, Product Type & Application
- 4.5 Global Retinal Disorders Therapy Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Retinal Disorders Therapy Market CR5 and HHI
- 4.6.3 2025 Retinal Disorders Therapy Tier 1, Tier 2, and Tier 3
5 Retinal Disorders Therapy Market Size by Type
- 5.1 Global Retinal Disorders Therapy Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Retinal Disorders Therapy Revenue by Type (2021-2032)
- 5.3 Global Retinal Disorders Therapy Revenue Market Share by Type (2021-2032)
6 Retinal Disorders Therapy Market Size by Application
- 6.1 Global Retinal Disorders Therapy Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Retinal Disorders Therapy Revenue by Application (2021-2032)
- 6.3 Global Retinal Disorders Therapy Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 ALLERGAN
- 7.1.1 ALLERGAN Company Information
- 7.1.2 ALLERGAN Business Overview
- 7.1.3 ALLERGAN Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
- 7.1.4 ALLERGAN Retinal Disorders Therapy Product Portfolio
- 7.1.5 ALLERGAN Recent Developments
- 7.2 Alimera Sciences
- 7.2.1 Alimera Sciences Company Information
- 7.2.2 Alimera Sciences Business Overview
- 7.2.3 Alimera Sciences Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
- 7.2.4 Alimera Sciences Retinal Disorders Therapy Product Portfolio
- 7.2.5 Alimera Sciences Recent Developments
- 7.3 Bausch & Lomb
- 7.3.1 Bausch & Lomb Company Information
- 7.3.2 Bausch & Lomb Business Overview
- 7.3.3 Bausch & Lomb Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
- 7.3.4 Bausch & Lomb Retinal Disorders Therapy Product Portfolio
- 7.3.5 Bausch & Lomb Recent Developments
- 7.4 Bristol-Myers Squibb
- 7.4.1 Bristol-Myers Squibb Company Information
- 7.4.2 Bristol-Myers Squibb Business Overview
- 7.4.3 Bristol-Myers Squibb Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
- 7.4.4 Bristol-Myers Squibb Retinal Disorders Therapy Product Portfolio
- 7.4.5 Bristol-Myers Squibb Recent Developments
- 7.5 Genentech
- 7.5.1 Genentech Company Information
- 7.5.2 Genentech Business Overview
- 7.5.3 Genentech Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
- 7.5.4 Genentech Retinal Disorders Therapy Product Portfolio
- 7.5.5 Genentech Recent Developments
- 7.6 Genzyme
- 7.6.1 Genzyme Company Information
- 7.6.2 Genzyme Business Overview
- 7.6.3 Genzyme Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
- 7.6.4 Genzyme Retinal Disorders Therapy Product Portfolio
- 7.6.5 Genzyme Recent Developments
- 7.7 Janssen Biotech
- 7.7.1 Janssen Biotech Company Information
- 7.7.2 Janssen Biotech Business Overview
- 7.7.3 Janssen Biotech Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
- 7.7.4 Janssen Biotech Retinal Disorders Therapy Product Portfolio
- 7.7.5 Janssen Biotech Recent Developments
- 7.8 OCULAR THERAPEUTIX
- 7.8.1 OCULAR THERAPEUTIX Company Information
- 7.8.2 OCULAR THERAPEUTIX Business Overview
- 7.8.3 OCULAR THERAPEUTIX Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
- 7.8.4 OCULAR THERAPEUTIX Retinal Disorders Therapy Product Portfolio
- 7.8.5 OCULAR THERAPEUTIX Recent Developments
- 7.9 Swedish Orphan Biovitrum
- 7.9.1 Swedish Orphan Biovitrum Company Information
- 7.9.2 Swedish Orphan Biovitrum Business Overview
- 7.9.3 Swedish Orphan Biovitrum Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
- 7.9.4 Swedish Orphan Biovitrum Retinal Disorders Therapy Product Portfolio
- 7.9.5 Swedish Orphan Biovitrum Recent Developments
- 7.10 UCBCares
- 7.10.1 UCBCares Company Information
- 7.10.2 UCBCares Business Overview
- 7.10.3 UCBCares Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
- 7.10.4 UCBCares Retinal Disorders Therapy Product Portfolio
- 7.10.5 UCBCares Recent Developments
- 7.11 AbbVie
- 7.11.1 AbbVie Company Information
- 7.11.2 AbbVie Business Overview
- 7.11.3 AbbVie Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
- 7.11.4 AbbVie Retinal Disorders Therapy Product Portfolio
- 7.11.5 AbbVie Recent Developments
- 7.12 Eyebright Medical
- 7.12.1 Eyebright Medical Company Information
- 7.12.2 Eyebright Medical Business Overview
- 7.12.3 Eyebright Medical Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
- 7.12.4 Eyebright Medical Retinal Disorders Therapy Product Portfolio
- 7.12.5 Eyebright Medical Recent Developments
- 7.13 Aier Eye Hospital
- 7.13.1 Aier Eye Hospital Company Information
- 7.13.2 Aier Eye Hospital Business Overview
- 7.13.3 Aier Eye Hospital Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
- 7.13.4 Aier Eye Hospital Retinal Disorders Therapy Product Portfolio
- 7.13.5 Aier Eye Hospital Recent Developments
- 7.14 Alcon Holdings, Inc.
- 7.14.1 Alcon Holdings, Inc. Company Information
- 7.14.2 Alcon Holdings, Inc. Business Overview
- 7.14.3 Alcon Holdings, Inc. Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
- 7.14.4 Alcon Holdings, Inc. Retinal Disorders Therapy Product Portfolio
- 7.14.5 Alcon Holdings, Inc. Recent Developments
- 7.15 Huaxia Eye Hospital
- 7.15.1 Huaxia Eye Hospital Company Information
- 7.15.2 Huaxia Eye Hospital Business Overview
- 7.15.3 Huaxia Eye Hospital Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
- 7.15.4 Huaxia Eye Hospital Retinal Disorders Therapy Product Portfolio
- 7.15.5 Huaxia Eye Hospital Recent Developments
- 7.16 Kanghong Pharmaceutical
- 7.16.1 Kanghong Pharmaceutical Company Information
- 7.16.2 Kanghong Pharmaceutical Business Overview
- 7.16.3 Kanghong Pharmaceutical Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
- 7.16.4 Kanghong Pharmaceutical Retinal Disorders Therapy Product Portfolio
- 7.16.5 Kanghong Pharmaceutical Recent Developments
- 7.17 Roche
- 7.17.1 Roche Company Information
- 7.17.2 Roche Business Overview
- 7.17.3 Roche Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
- 7.17.4 Roche Retinal Disorders Therapy Product Portfolio
- 7.17.5 Roche Recent Developments
- 7.18 Xingqi Pharmaceutical
- 7.18.1 Xingqi Pharmaceutical Company Information
- 7.18.2 Xingqi Pharmaceutical Business Overview
- 7.18.3 Xingqi Pharmaceutical Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
- 7.18.4 Xingqi Pharmaceutical Retinal Disorders Therapy Product Portfolio
- 7.18.5 Xingqi Pharmaceutical Recent Developments
8 North America
- 8.1 North America Retinal Disorders Therapy Revenue (2021-2032)
- 8.2 North America Retinal Disorders Therapy Revenue by Type (2021-2032)
- 8.2.1 North America Retinal Disorders Therapy Revenue by Type (2021-2026)
- 8.2.2 North America Retinal Disorders Therapy Revenue by Type (2027-2032)
- 8.3 North America Retinal Disorders Therapy Revenue Share by Type (2021-2032)
- 8.4 North America Retinal Disorders Therapy Revenue by Application (2021-2032)
- 8.4.1 North America Retinal Disorders Therapy Revenue by Application (2021-2026)
- 8.4.2 North America Retinal Disorders Therapy Revenue by Application (2027-2032)
- 8.5 North America Retinal Disorders Therapy Revenue Share by Application (2021-2032)
- 8.6 North America Retinal Disorders Therapy Revenue by Country
- 8.6.1 North America Retinal Disorders Therapy Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Retinal Disorders Therapy Revenue by Country (2021-2026)
- 8.6.3 North America Retinal Disorders Therapy Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
9 Europe
- 9.1 Europe Retinal Disorders Therapy Revenue (2021-2032)
- 9.2 Europe Retinal Disorders Therapy Revenue by Type (2021-2032)
- 9.2.1 Europe Retinal Disorders Therapy Revenue by Type (2021-2026)
- 9.2.2 Europe Retinal Disorders Therapy Revenue by Type (2027-2032)
- 9.3 Europe Retinal Disorders Therapy Revenue Share by Type (2021-2032)
- 9.4 Europe Retinal Disorders Therapy Revenue by Application (2021-2032)
- 9.4.1 Europe Retinal Disorders Therapy Revenue by Application (2021-2026)
- 9.4.2 Europe Retinal Disorders Therapy Revenue by Application (2027-2032)
- 9.5 Europe Retinal Disorders Therapy Revenue Share by Application (2021-2032)
- 9.6 Europe Retinal Disorders Therapy Revenue by Country
- 9.6.1 Europe Retinal Disorders Therapy Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Retinal Disorders Therapy Revenue by Country (2021-2026)
- 9.6.3 Europe Retinal Disorders Therapy Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Netherlands
- 9.6.9 Nordic Countries
10 China
- 10.1 China Retinal Disorders Therapy Revenue (2021-2032)
- 10.2 China Retinal Disorders Therapy Revenue by Type (2021-2032)
- 10.2.1 China Retinal Disorders Therapy Revenue by Type (2021-2026)
- 10.2.2 China Retinal Disorders Therapy Revenue by Type (2027-2032)
- 10.3 China Retinal Disorders Therapy Revenue Share by Type (2021-2032)
- 10.4 China Retinal Disorders Therapy Revenue by Application (2021-2032)
- 10.4.1 China Retinal Disorders Therapy Revenue by Application (2021-2026)
- 10.4.2 China Retinal Disorders Therapy Revenue by Application (2027-2032)
- 10.5 China Retinal Disorders Therapy Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Retinal Disorders Therapy Revenue (2021-2032)
- 11.2 Asia Retinal Disorders Therapy Revenue by Type (2021-2032)
- 11.2.1 Asia Retinal Disorders Therapy Revenue by Type (2021-2026)
- 11.2.2 Asia Retinal Disorders Therapy Revenue by Type (2027-2032)
- 11.3 Asia Retinal Disorders Therapy Revenue Share by Type (2021-2032)
- 11.4 Asia Retinal Disorders Therapy Revenue by Application (2021-2032)
- 11.4.1 Asia Retinal Disorders Therapy Revenue by Application (2021-2026)
- 11.4.2 Asia Retinal Disorders Therapy Revenue by Application (2027-2032)
- 11.5 Asia Retinal Disorders Therapy Revenue Share by Application (2021-2032)
- 11.6 Asia Retinal Disorders Therapy Revenue by Country
- 11.6.1 Asia Retinal Disorders Therapy Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Retinal Disorders Therapy Revenue by Country (2021-2026)
- 11.6.3 Asia Retinal Disorders Therapy Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Retinal Disorders Therapy Revenue (2021-2032)
- 12.2 SAMEA Retinal Disorders Therapy Revenue by Type (2021-2032)
- 12.2.1 SAMEA Retinal Disorders Therapy Revenue by Type (2021-2026)
- 12.2.2 SAMEA Retinal Disorders Therapy Revenue by Type (2027-2032)
- 12.3 SAMEA Retinal Disorders Therapy Revenue Share by Type (2021-2032)
- 12.4 SAMEA Retinal Disorders Therapy Revenue by Application (2021-2032)
- 12.4.1 SAMEA Retinal Disorders Therapy Revenue by Application (2021-2026)
- 12.4.2 SAMEA Retinal Disorders Therapy Revenue by Application (2027-2032)
- 12.5 SAMEA Retinal Disorders Therapy Revenue Share by Application (2021-2032)
- 12.6 SAMEA Retinal Disorders Therapy Revenue by Country
- 12.6.1 SAMEA Retinal Disorders Therapy Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Retinal Disorders Therapy Revenue by Country (2021-2026)
- 12.6.3 SAMEA Retinal Disorders Therapy Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst